Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment

被引:21
作者
Lachowiez, Curtis A. [1 ]
Reville, Patrick K. [1 ]
Kantarjian, Hagop [2 ]
Jabbour, Elias [2 ]
Borthakur, Gautam [2 ]
Daver, Naval [2 ]
Issa, Ghayas [2 ]
Furudate, Ken [3 ]
Tanaka, Tomoyuki [3 ]
Pierce, Sherry [2 ]
Tang, Guilin [4 ]
Patel, Keyur P.
Medeiros, Jeffrey
Abbas, Hussein A. [2 ]
Haddad, Fadi [2 ]
Hammond, Daniel [2 ]
Short, Nicholas J. [2 ]
Maiti, Abhishek [2 ]
Yilmaz, Musa [2 ]
Sasaki, Koji [2 ]
Takahashi, Koichi [2 ]
Pemmaraju, Naveen [2 ]
Konopleva, Marina [2 ]
Garcia-Manero, Guillermo [2 ]
Ravandi, Farhad [2 ]
Kadia, Tapan M. [2 ]
Loghavi, Sanam [4 ]
DiNardo, Courtney D. [2 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept hematopathol, Houston, TX 77030 USA
关键词
PROGNOSTIC-SIGNIFICANCE; AML; RECOMMENDATIONS; AZACITIDINE; DIAGNOSIS;
D O I
10.1002/ajh.26694
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Isocitrate dehydrogenase 1 or 2 (IDH1 or IDH2) mutations occur frequently in newly diagnosed (ND) acute myeloid leukemia (AML) often with co-occurring NPM1 mutations, which may influence treatment outcomes. Detailed analysis of IDH-mutated AML treated with venetoclax and influence of co-occurring NPM1 mutations remains unclear. This retrospective single-center cohort study evaluated clinical and molecular demographics,response and survival, and impact of co-occurring NPM1 mutations in patients with IDH1 or IDH2-mutated AML. 556 patients with IDH1, IDH2, and/or NPM1 mutated AML were included. Patients with IDH1(mut) AML (N = 119) were more likely to have older age, sAML, ELN-adverse risk disease, and adverse-risk cytogenetics compared to those with IDH2(mut) (N = 229) or IDHwt/NPM1(mut) AML (N = 208). In multivariate analysis, patients with IDH2(mut) (HR 0.61 [95%CI: 0.43-0.88], p value: .007) or IDHwt/NPM1(mut) (HR 0.65 [95% CI: 0.45-0.94], p value: .024) AML had a decreased risk of death versus IDH1(mut) AML. Venetoclax-based lower-intensity regimens partially abrogated the detrimental effect of IDH1(mut) with similar OS observed between IDH1(mut)/NPM1(wt), IDH2(mut)/NPM1(wt), and IDHwt/NPM1(mut) AML. With regards to the influence of IDHmut/NPM1(mut) cases, IC improved survival in IDH2(mut)/NPM1(mut) versus IDH2(mut)/NPM1(wt) AML (HR: 0.54 [95% CI: 0.2644-1.082], p value: .077), while venetoclax-based therapy improved survival in IDH1(mut)/NPM1(mut) versus IDH1(mut)/NPM1(wt) AML (HR: 0.094 [95% CI: 0.01-0.74], p value: .0056). Differing outcomes were observed in IDH1(mut) versus IDH2(mut) or NPM1(mut) AML which were influenced by co-occurring NPM1 mutations and partially abrogated with venetoclax-based therapy. Given the differing biology and survival in IDH1(mut) AML, investigations incorporating molecularly targeted therapies such as IDH inhibitors remain warranted in this subgroup.
引用
收藏
页码:1443 / 1452
页数:10
相关论文
共 42 条
  • [21] Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML
    I H I M Hollink
    C M Zwaan
    M Zimmermann
    T C J M Arentsen-Peters
    R Pieters
    J Cloos
    G J L Kaspers
    S S N de Graaf
    J Harbott
    U Creutzig
    D Reinhardt
    M M van den Heuvel-Eibrink
    C Thiede
    Leukemia, 2009, 23 : 262 - 270
  • [22] Outcomes of Older Patients with NPM1 Mutated and FLT3-ITD Negative Acute Myeloid Leukemia Receiving Allogeneic Transplantation
    Jentzsch, Madlen
    Grimm, Juliane
    Bill, Marius
    Goldmann, Karoline
    Schulz, Julia
    Niederwieser, Dietger
    Platzbecker, Uwe
    Schwind, Sebastian
    HEMASPHERE, 2020, 4 (01):
  • [23] Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors
    Bewersdorf, Jan Philipp
    Shallis, Rory M.
    Derkach, Andriy
    Goldberg, Aaron D.
    Stein, Anthony
    Stein, Eytan M.
    Marcucci, Guido
    Zeidan, Amer M.
    Shimony, Shai
    DeAngelo, Daniel J.
    Stone, Richard M.
    Aldoss, Ibrahim
    Ball, Brian J.
    Stahl, Maximilian
    LEUKEMIA & LYMPHOMA, 2023, 64 (01) : 188 - 196
  • [24] Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax-based therapy
    Weng, Guangyang
    Huang, Jingya
    An, Na
    Zhang, Yu
    Yu, Guopan
    Sun, Zhiqiang
    Lin, Dongjun
    Deng, Lan
    Liang, Xinquan
    Xiao, Jie
    Zhang, Hongyu
    Guo, Ziwen
    He, Xin
    Jin, Hua
    Liu, Qifa
    Du, Xin
    CANCER MEDICINE, 2024, 13 (02):
  • [25] Integrin expression and adhesivity to fibronectin in primary acute myeloid leukemia cells: Impact of NPM1 and FLT3 mutations
    Kuzelova, Katerina
    Obr, Adam
    Markova, Jana
    Gasova, Zdenka
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 105 (05) : 578 - 587
  • [26] Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations
    Freeman, Sylvie D.
    Hills, Robert K.
    Virgo, Paul
    Khan, Naeem
    Couzens, Steve
    Dillon, Richard
    Gilkes, Amanda
    Upton, Laura
    Nielsen, Ove Juul
    Cavenagh, James D.
    Jones, Gail
    Khwaja, Asim
    Cahalin, Paul
    Thomas, Ian
    Grimwade, David
    Burnett, Alan K.
    Russell, Nigel H.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15) : 1486 - +
  • [27] Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens
    Baden, David
    Zukunft, Sven
    Hernandez, Gema
    Wolgast, Nadine
    Steinhaeuser, Sophie
    Pohlmann, Alexander
    Schliemann, Christoph
    Mikesch, Jan-Henrik
    Steffen, Bjoern
    Sauer, Tim
    Hanoun, Maher
    Schaefer-Eckart, Kerstin
    Krause, Stefan W.
    Haenel, Mathias
    Einsele, Hermann
    Jost, Edgar
    Bruemmendorf, Tim H.
    Scholl, Sebastian
    Hochhaus, Andreas
    Neubauer, Andreas
    Burchert, Andreas
    Kaufmann, Martin
    Niemann, Dirk
    Schaich, Markus
    Blau, Wolfgang
    Kiani, Alexander
    Goerner, Martin
    Kaiser, Ulrich
    Kullmer, Johannes
    Weber, Thomas
    Berdel, Wolfgang E.
    Ehninger, Gerhard
    Mueller-Tidow, Carsten
    Platzbecker, Uwe
    Serve, Hubert
    Bornhaeuser, Martin
    Roellig, Christoph
    Baldus, Claudia D.
    Fransecky, Lars
    HAEMATOLOGICA, 2024, 109 (08) : 2469 - 2477
  • [28] IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
    Paschka, Peter
    Schlenk, Richard F.
    Gaidzik, Verena I.
    Habdank, Marianne
    Kroenke, Jan
    Bullinger, Lars
    Spaeth, Daniela
    Kayser, Sabine
    Zucknick, Manuela
    Goetze, Katharina
    Horst, Heinz-A.
    Germing, Ulrich
    Doehner, Hartmut
    Doehner, Konstanze
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (22) : 3636 - 3643
  • [29] Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1 and rearranged CBF
    Jimenez-Vicente, Carlos
    Martinez-Roca, Alexandra
    Pomares, Helena
    Castano-Diez, Sandra
    Guijarro, Francesca
    Lopez-Guerra, Monica
    Bataller, Alex
    Esteban, Daniel
    Cortes-Bullich, Albert
    Perez-Valencia, Amanda Isabel
    Guardia-Torrelles, Ares
    Zugasti, Ines
    Rovira, Montserrat
    Fernandez-Aviles, Francesc
    Colomer, Dolors
    Arnan, Montserrat
    Diaz-Beya, Marina
    Esteve, Jordi
    LEUKEMIA RESEARCH, 2023, 135
  • [30] Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study
    Zhao, Lei
    Yang, Jinjun
    Chen, Mengran
    Xiang, Xinrong
    Ma, Hongbing
    Niu, Ting
    Gong, Yuping
    Chen, Xinchuan
    Liu, Jiazhuo
    Wu, Yu
    ANNALS OF HEMATOLOGY, 2024, 103 (04) : 1197 - 1209